Biogen Inc (BIIB) carries a ŷRobot AI score of 45 out of 100. The model's fair value estimate is $215.25, 5.2% below the last close of $227.07. The chart signal reads Sell.
| Metric | BIIB |
|---|---|
| AI score | 45 / 100 |
| Chart signal | Sell |
| Fair value estimate | $215.25 |
| Upside to fair value | -5.2% |
| Previous close | $227.07 |
| P/E | 39.37 |
| Price / sales | 3.19 |
| Market cap | $33.79B |
| EPS | 5.55 |
| Revenue growth | -1.3% |
| 1-year price change | -3.4% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
As of Sep 29, 2026, ŷRobot's fair-value model estimates Biogen Inc (BIIB) at $215.25 against a last close of $227.07, implying 5.2% downside to the model's estimate.
The chart-signal model classifies BIIB as Neutral as of Sep 29, 2026, with a signal score of -0.14 on a -1 to 1 scale.
BIIB scores 45 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Sep 29, 2026.
BIIB trades at 39.4 times earnings and 3.2 times sales as of Sep 29, 2026.
ŷRobot's seasonal forecast curve for BIIB reads -3.1% at 30 days, -2.5% at 90 days, and -3.4% at one year as of Sep 29, 2026. Seasonal tendencies are historical patterns, not predictions.
Biogen Inc's revenue growth is -1.3% and free-cash-flow growth is -49.6% on the latest reported figures.
BIIB chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.